Anti-Rat CD28 Antibody (JJ319) 

Anti-Rat CD28 Antibody (JJ319) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat CD28. Anti-Rat CD28 Antibody (JJ319) activates T cells in the presence of T cell receptor-stimulation. Anti-Rat CD28 Antibody (JJ319) can be used for the researches of inflammation and immunology, such as transplantation and neuritis^[1][2].

CD28

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Rat CD28 Antibody (JJ319) (4 mg/kg, 4 days prior to transplantation) prolongs graft survival in combination with donor-specific blood transfusion treatment in rat liver transplantation models^[1].
Anti-Rat CD28 Antibody (JJ319) (1 mg, i.p., at day 0 and day 12) reduces disease severity in experimental autoimmune neuritis rats models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

25660  [NCBI]

P31042

150 kDa

[Anti-Rat CD28 Antibody (JJ319)]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Urakami H, et al. Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc. 2006 Dec;38(10):3244-6.  [Content Brief]

  [2]. Schmidt J, et al. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol. 2003 Jul;140(1-2):143-52.  [Content Brief]